Top Non-Small Cell Lung Cancer Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Non-Small Cell Lung Cancer Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Non-Small Cell Lung Cancer industry players.

Non-Small Cell Lung Cancer Market Competitive Landscape

  • Different techniques are being used by players to broaden their product offerings and expand their geographic reach in response to the demand for lung cancer therapies. Product innovation, alliances and partnerships, and mergers are a few of the primary tactics used by participants in the worldwide lung cancer treatments market. The major players in the market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Astrazeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim International Gmbh, Merck & Co., Inc., Celgene Corporation, Amgen Inc., Sanofi, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Allergan, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and Astellas Pharma Inc.

Top Players in the Global Non-Small Cell Lung Cancer Market 

  • F. Hoffmann-La Roche Ltd. (Switzerland) 
  • AstraZeneca (United Kingdom) 
  • Bristol-Myers Squibb Company (United States) 
  • Merck & Co., Inc. (United States) 
  • Novartis AG (Switzerland) 
  • Pfizer Inc. (United States) 
  • Takeda Pharmaceutical Company Limited (Japan) 
  • Bayer AG (Germany) 
  • Eli Lilly and Company (United States) 
  • GlaxoSmithKline plc (United Kingdom) 
  • Sanofi (France) 
  • AbbVie Inc. (United States) 
  • Johnson & Johnson (United States) 
  • Gilead Sciences, Inc. (United States) 
  • Amgen Inc. (United States) 
  • Boehringer Ingelheim GmbH (Germany) 
  • Daiichi Sankyo Company, Limited (Japan) 
  • Astellas Pharma Inc. (Japan) 
  • Biogen Inc. (United States) 
  • Regeneron Pharmaceuticals, Inc. (United States)

Non-Small Cell Lung Cancer Market

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

Top Players in the Global Non-Small Cell Lung Cancer Market  'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'AstraZeneca (United Kingdom) ', 'Bristol-Myers Squibb Company (United States) ', 'Merck & Co., Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Pfizer Inc. (United States) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Bayer AG (Germany) ', 'Eli Lilly and Company (United States) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Sanofi (France) ', 'AbbVie Inc. (United States) ', 'Johnson & Johnson (United States) ', 'Gilead Sciences, Inc. (United States) ', 'Amgen Inc. (United States) ', 'Boehringer Ingelheim GmbH (Germany) ', 'Daiichi Sankyo Company, Limited (Japan) ', 'Astellas Pharma Inc. (Japan) ', 'Biogen Inc. (United States) ', 'Regeneron Pharmaceuticals, Inc. (United States)'

Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Lung Cancer Market
Buy Now GET FREE SAMPLE
Lung Cancer Therapeutics Market
Buy Now GET FREE SAMPLE
Lung Cancer Surgery Market
Buy Now GET FREE SAMPLE
Oncology Market
Buy Now GET FREE SAMPLE
Cancer Immunotherapy Market
Buy Now GET FREE SAMPLE
Cancer Biological Therapy Market
Buy Now GET FREE SAMPLE
Cancer Cachexia Market
Buy Now GET FREE SAMPLE
Cancer Diagnostics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market

Report ID: SQMIG25K2005

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE